4D Molecular Therapeutics, Inc.
FDMT
$4.11
-$0.17-3.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -160.87M | -143.48M | -109.89M | -104.56M | -100.84M |
| Total Depreciation and Amortization | 6.71M | 6.43M | 6.13M | 5.93M | 5.75M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.04M | 18.76M | 19.06M | 20.05M | 18.67M |
| Change in Net Operating Assets | 537.00K | 4.92M | -446.00K | 1.60M | 630.00K |
| Cash from Operations | -134.59M | -113.37M | -85.15M | -76.97M | -75.79M |
| Capital Expenditure | -3.79M | -3.39M | -2.01M | -2.47M | -2.77M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -298.65M | -312.79M | -311.49M | -188.20M | 118.49M |
| Cash from Investing | -302.44M | -316.18M | -313.50M | -190.67M | 115.72M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 337.25M | 341.41M | 350.86M | 464.60M | 156.83M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 541.00K | 69.00K | 0.00 |
| Cash from Financing | 337.25M | 341.41M | 351.40M | 464.67M | 156.83M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.77M | -88.14M | -47.25M | 197.03M | 196.76M |
